Sino-American biotech BeiGene has now effected its previously announced transition, becoming BeOne Medicines (Nasdaq: ONC; HKEX: 06160; SSE: 688235) and redomiciling to Switzerland, marking a ...

Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic ...

US biotech GRIN Therapeutics has secured $140 million in Series D funding and signed a licensing deal with Italy's Angelini ...

US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ...

Texas, USA-based clinical-stage biopharma Savara (Nasdaq: SVRA) on Tuesday announced that the company received a refuse to ...

Germany’s Merck KGaA (MRK: DE) today announced the presentation of detailed positive results from Part 1 of the global Phase ...

German drug developer InflaRx (Nasdaq: IFRX) saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it ...

US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

US pharma major Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private ...

New York-based neurosciences company Gilgamesh Pharmaceuticals yesterday announced Phase IIa results for GM-2505, a novel, ...